751 Prognostic factors affecting disease-free-survival in locally advanced cervical cancer

Introduction/Background Cervical cancer ranks fourth in global female incidence and mortality, with approximately 604,000 new diagnoses and 342,000 deaths in 2020. This study was performed to identify the factors that could predict disease-free survival (DFS) in patients treated with curative intent for locally advanced cervical cancer. Methodology We conducted a retrospective study at Salah Azaiez Institute of Oncology from January 1, 2010, to December 31, 2020, including 141 patients treated with curative intent for locally advanced cervical cancer (International Federation of Gynecology and Obstetrics Stages IB3-IVA). Clinical and pathologic variables were analyzed using univariate analyses. DFS was performed by the Kaplan-Meier method and the log-rank test. Results One Hundred Forty-One patients were treated with curative intent for locally advanced cervical cancer. The mean age was 54.63 years(34–63). Among these patients, 122 underwent Radio-chemotherapy followed by R0 surgery (G1), while 19 patients had only Radio-chemotherapy with complete response (G2)(clinical, radiological, and histological). Sixteen women presented recurrence in G1 with a median time of 24.31 months vs. 6 patients in G2 with a median time of 15.17 months. Three-year DFS of groups 1 and 2 were 85% and 64.8% respectively with no statistically significant difference between them p(0.068). The three-year DFS of the 141 women was 81.7%. Histological grade p(0.009) lymphovascular space involvement (LVSI) p(0.000), pelvic lymph node metastases on MRI p(0.037), bladder invasion on MRI p(0.003), and FIGO stage p(0.002) were prognostic factors that affected DFS. DFS was not significantly different for age p(0.782), tumor size p(0.287), parametrial invasion p(0.096), and cell type p(0.225). Conclusion Histological Grade 2–3, LVSI, pelvic lymph node metastases on MRI, bladder invasion on MRI, and FIGO stage were prognostic factors for DFS in locally advanced cervical cancer patients. Disclosures All authors declare that there are no conflicts of interest.